Manufacturing norms, inspection issues led to USFDA alert on Divis Laboratories

By: |
Published: March 22, 2017 8:43:38 PM

Divis Laboratories today said the US health regulator issued import alert for products made at one of its units at Visakhapatnam citing violation of manufacturing norms and refusal of inspection.

USFDA, Divis Laboratories, Visakhapatnam, BSE filing, GMPThe company said it has already initiated measures to address the concerns raised by the USFDA.(Reuters)

Divis Laboratories today said the US health regulator issued import alert for products made at one of its units at Visakhapatnam citing violation of manufacturing norms and refusal of inspection. The company said it has already initiated measures to address the concerns raised by the USFDA. “We wish to update that the import alert by USFDA for the products manufactured at the company’s Unit-II at Visakhapatnam was issued under two clauses 66-40 & 99-32 of the FDA regulations,” Divis Laboratories said in a BSE filing.

As per US Food and Drug Administration (USFDA), a import alert under 66-40 entails “detention without physical examination” of drugs from firms which have not met drug GMPs, while alert under 99-32 is issued to “firms refusing FDA foreign establishment inspection”.

You may also like to watch:

Divis said: “The company has already initiated necessary measures to address the concerns raised by the US-FDA and is making all efforts to fully meet the compliance requirements.”

The regulator had exempted ten products, including Levetiracetam, Gabapentin, Lamotrigine, Capecitabine, Naproxen sodium and BOC core succinate, from the import alert.

Divis stock closed 1.19 per cent down at Rs 626.80 on BSE.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Next Stories
1Coal India to miss production target, sales to grow marginally
2Merger benefits to accrue only from Q3 2017-18: SBI
3Airbnb adopts new name Aibiying, doubles investment to woo China